---
title: "Penny Stocks: Why Is Celularity (CELU) Stock Trending Today?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290348450.md"
description: "Celularity (CELU) stock is trending due to a strategic pivot toward longevity-focused cell therapies, an asset sale aimed at improving its balance sheet, and a new commercial push in Florida. Despite these positive developments creating a high-volatility setup for the micro-cap biotech, shares dropped 5.55% on Thursday, closing at $0.75."
datetime: "2026-06-21T11:41:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290348450.md)
  - [en](https://longbridge.com/en/news/290348450.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290348450.md)
generator: "portal-rs"
---

# Penny Stocks: Why Is Celularity (CELU) Stock Trending Today?

Celularity Inc. (CELU), a micro-cap biotech company developing placental-derived cell therapies, is drawing investor attention after a cluster of company-specific updates gave traders a fresh turnaround story to follow.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

The stock is trending as investors react to Celularity's sharper pivot toward longevity-focused cell therapy, a balance-sheet-improving asset sale, and a new commercial push tied to Florida's regenerative medicine framework. For a low-priced biotech with listing and financing risks still in the background, that mix has created a high-volatility setup.

Meanwhile, CELU shares dropped 5.55% on Thursday, closing at $0.75.

### Related Stocks

- [CELUW.US](https://longbridge.com/en/quote/CELUW.US.md)
- [CELU.US](https://longbridge.com/en/quote/CELU.US.md)

## Related News & Research

- [Celularity Restores Nasdaq Compliance on Key Listing Standards](https://longbridge.com/en/news/298935226.md)
- [Celularity remains out of compliance with Nasdaq periodic reporting rule due to delayed SEC filings](https://longbridge.com/en/news/298923379.md)
- [Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus | NTHI Stock News](https://longbridge.com/en/news/299061532.md)
- [NTLA: Late-stage gene editing therapies for HAE and TTR advance, with FDA review and strong market prospects](https://longbridge.com/en/news/298966653.md)
- [SRRK: ISEMBYLD receives FDA approval as the first muscle-targeted SMA therapy, launching in the U.S](https://longbridge.com/en/news/298774302.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**